P2X3 Receptor Antagonists for Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and specific agonists and antagonists for P2X receptor subtypes, particularly P2X3, which are crucial for regulating pain and other physiological processes, due to susceptibility to enzymatic degradation and the lack of receptor subtype-specific compounds.
Innovation Solution
Development of novel P2X3 receptor antagonists with specific structural formulas that can effectively modulate P2X3 receptors to treat pain and associated diseases, including peripheral and inflammatory pain, by using compounds with specific structural features such as various substituents on aryl, heterocyclyl, and alkyl groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional P2X receptor antagonists are used, then some pain relief may be achieved, but lack of specificity leads to poor efficacy and unwanted side effects
Solution Approach 1:
The patent applies local quality by introducing specific structural features at particular positions in the molecular structure. The compound contains a pyridine ring at position 3, a pyrimidine ring at position 5, and specific substituent patterns (R1-R6 groups) that create localized chemical properties selective for P2X3 receptors. This localized structural differentiation enables high receptor subtype specificity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent employs composite materials by combining multiple functional molecular moieties into a single compound structure. The molecule integrates a pyridine-containing fragment, a pyrimidine-containing fragment, and various substituent groups (including aromatic, heterocyclic, and alkyl groups) that work synergistically to achieve both high affinity binding to P2X3 receptors and selective activity, thereby resolving the contradiction between specificity and efficacy.
2Adaptability or versatility
If non-specific P2X antagonists are used, then broader receptor activity is achieved, but increased susceptibility to enzymatic degradation
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations) to optimize both receptor selectivity and metabolic stability. The compound incorporates specific substituents (R1-R6) that can be modified to change pharmacokinetic properties. For example, introducing fluorine atoms or specific aromatic groups can enhance metabolic stability while maintaining P2X3 selectivity, thus resolving the contradiction between versatility and stability.
3Measurement precision
If existing P2X3 antagonists are used, then some pain transmission blocking is achieved, but insufficient specificity causes treatment of wrong conditions
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a pyridine-containing segment (positions 3 and 4), a pyrimidine-containing segment (position 5), and variable substituent segments (R1-R6). Each segment contributes specific binding characteristics, with the pyridine and pyrimidine cores providing high affinity P2X3 binding, while the substituents fine-tune selectivity and reduce off-target effects. This segmentation enables precise receptor targeting with minimal side effects.
Data Source
AI summary
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.